target directory

sars cov 2 spike protein clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT05364047

Source recordAI-normalized

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) in Chinese People Aged 18 Years and Over

AIM Vaccine Co., Ltd. is conducting a Phase I clinical trial of the mRNA vaccine LVRNA009 targeting the SARS-CoV-2 virus in the Chinese population aged 18 years and older. The trial aims to assess safety, tolerability, and preliminary immunogenicity. Given the ongoing global demand for effective COVID-19 vaccines, this asset has potential commercial value, particularly in the Chinese market where vaccination efforts continue. The competitive landscape includes established players like Pfizer-BioNTech and Moderna, which may pose challenges in market penetration. Diligence is warranted to evaluate the trial's progress and any emerging data that could influence market positioning.

AI analysis

Indication: COVID-19

Modality: RNA therapy

Target: SARS-CoV-2 Spike Protein

Sponsor: AIM Vaccine Co., Ltd.

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 21, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: SARS-CoV-2 Spike Protein

View original source fields

Condition raw: COVID-19

Condition normalized: COVID-19

Modality raw: RNA therapy

Modality normalized: RNA therapy

Target raw: SARS-CoV-2 Spike Protein

Target normalized: SARS-CoV-2 Spike Protein

Open report

NCT05016622

Source recordAI-normalized

Safety and Efficacy of Booster Doses of COVID-19 Vaccine in Immunocompromised Patients With a Cancer Diagnosis

The study, sponsored by Montefiore Medical Center, aimed to evaluate the safety and efficacy of COVID-19 vaccine booster doses in immunocompromised cancer patients who did not develop an adequate antibody response after the primary vaccination series. Given the ongoing need for effective vaccination strategies in vulnerable populations, the results could inform future vaccine recommendations and public health policies. The termination of the study due to funding issues and decreased engagement may limit the data available for market analysis, but it highlights the challenges in conducting clinical trials in this demographic. The competitive landscape includes other ongoing studies targeting similar patient populations, which may impact the market positioning of the findings from this trial.

AI analysis

Indication: Cancer

Modality: protein therapy

Target: SARS-CoV-2 Spike Protein

Sponsor: Montefiore Medical Center

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 21, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: SARS-CoV-2 Spike Protein

NCT05047640

Source recordAI-normalized

A Single-Blind, Randomized, Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as a Booster Dose After Completion of BNT162b2 Vaccine in Solid Organ Transplant Recipients

The trial aimed to compare the immunogenicity of two COVID-19 booster vaccines, BNT162b2 and JNJ-78436735, in solid organ transplant recipients, a population at high risk for severe COVID-19 outcomes. The termination of the trial due to recruitment difficulties may indicate challenges in engaging this specific patient population, which could affect the commercial viability of both vaccine candidates in this niche market. The results may provide insights into the efficacy of different booster strategies, potentially influencing future vaccination guidelines and market positioning for both sponsors.

AI analysis

Indication: Covid19

Modality: vaccine

Target: SARS-CoV-2 Spike Protein

Sponsor: Giselle Guerra

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 07, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: SARS-CoV-2 Spike Protein

View original source fields

NCT04961229

Source recordAI-normalized

Booster Dose of mRNA SARS-CoV-2 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response With or Without Immunosuppression Reduction - Protocol for a Randomised Controlled Trial (BECAME Study)

The BECAME study, sponsored by Dafna Yahav at Rabin Medical Center, aims to address the inadequate humoral response to mRNA SARS-CoV-2 vaccination in kidney transplant recipients. This population is at heightened risk for severe COVID-19 outcomes, creating a significant market opportunity for enhanced vaccination strategies. The trial compares the efficacy of a third BNT162b2 vaccine dose with and without immunosuppression reduction, potentially leading to improved patient outcomes and increased adoption of booster vaccination protocols. The results could inform clinical guidelines and influence market dynamics for COVID-19 vaccines, particularly in immunocompromised populations. Given the ongoing need for effective vaccination strategies in vulnerable groups, successful outcomes may enhance the competitive positioning of the BNT162b2 vaccine in the market.

AI analysis

Indication: COVID-19 Acute Respiratory Distress Syndrome

Modality: monoclonal antibody

Target: SARS-CoV-2 spike protein

Sponsor: dafna yahav

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 03, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: SARS-CoV-2 spike protein